论文部分内容阅读
目的:观察必可酮(丙酸倍氯米松气雾剂)、宁肺丸、阿罗格治疗尘螨过敏的咳嗽变异型哮喘(CVA)患者肺功能的改善情况和1年复发率。方法:将138例CVA患者随机分为3组,每组46例。治疗组A:予必可酮、宁肺丸、阿罗格治疗;治疗组B:予必可酮、宁肺丸治疗;对照组:予必可酮治疗。疗程12周,观察治疗前及治疗12周时的第1秒用力呼气容量(FEV)1、用力肺活量(FVC)、呼气峰流速(PEF),以及治疗满1年时每组复发率。结果:纳入统计,治疗组A 43例,治疗组B44例,对照组43例,各组FVC、FEV1、PEF指标治疗前后比较,差异均有显著性意义(P<0.05)。FVC治疗前后差值组间比较,治疗组A较其它2组均有明显变化(P<0.05)。FEV1、PEF治疗前后差值组间比较,差异无显著性意义(P>0.05)。1年复发率治疗组A 46.5%、治疗组B 63.6%、对照组74.4%。3组复发率比较,差异有显著性意义(P<0.05,)。结论:必可酮、宁肺丸、阿罗格对尘螨过敏的CVA患者可明显改善其FVC,降低1年复发率,并且有可能改善CVA患者的小气道通气功能障碍。
OBJECTIVE: To observe the improvement of pulmonary function and the one-year recurrence rate of patients with cough variant asthma (CVA) who are allergic to beclomethasone (beclometasone dipropionate aerosol), ningfei pills and alopecia. Methods: 138 CVA patients were randomly divided into 3 groups, 46 cases in each group. Treatment group A: pre-Beketone, Ningfei pills, Arroyo treatment; treatment group B: to be ketone, Ningfei pills; control group: to be ketone medication. The course of treatment was 12 weeks. The forced expiratory volume in 1 second (FEV) 1, forced vital capacity (FVC) and peak expiratory flow (PEF) before and 12 weeks after treatment were observed, and the recurrence rates of each group were observed after one year of treatment. Results: According to the statistics, there were 43 cases in the treatment group, B44 cases in the treatment group and 43 cases in the control group. The differences of FVC, FEV1 and PEF before and after treatment in each group were statistically significant (P <0.05). Before and after FVC treatment difference between the two groups, treatment group A than the other two groups were significantly changed (P <0.05). Before and after FEV1 and PEF treatment, there was no significant difference between the two groups (P> 0.05). One-year relapse rate was 46.5% in treatment group A, 63.6% in treatment group B, and 74.4% in control group. The recurrence rate of the three groups was significantly different (P <0.05, P <0.05). Conclusion: CVA patients allergic to dust mite may significantly improve their FVC, reduce the recurrence rate of 1 year, and may improve the small airway ventilation dysfunction in CVA patients.